# Stryker completes acquisition of Amplitude Vascular Systems to add next-generation IVL technology to peripheral vascular portfolio
Canonical URL: https://biopharmsignal.com/news/SYK/stryker-completes-acquisition-of-amplitude-vascular-systems-to-add-next-generation-ivl-technology-to-peripheral-vascular-portfolio
Ticker: SYK
Company: Stryker
Source: Stryker
Published: 2026-05-07 20:05 EST
Original Source URL: https://investors.stryker.com
## Article Body
No article body is available yet.
## Recent Company News
- 2026-07-01 12:00 EST — [Stryker to announce second quarter 2026 financial results](https://biopharmsignal.com/news/SYK/stryker-to-announce-second-quarter-2026-financial-results-94b73874) — Source: Stryker
- 2026-05-07 20:05 EST — [Stryker completes acquisition of Amplitude Vascular Systems to add next-generation IVL technology to peripheral vascular portfolio](https://biopharmsignal.com/news/SYK/stryker-completes-acquisition-of-amplitude-vascular-systems-to-add-next-generation-ivl-technology-to-peripheral-vascular-portfolio) — Source: Stryker
- 2026-05-07 12:00 EST — [Stryker declares an $0.88 per share quarterly dividend](https://biopharmsignal.com/news/SYK/stryker-declares-an-0-88-per-share-quarterly-dividend-6211bc27) — Source: Stryker
- 2026-05-01 12:00 EST — [Stryker to participate in the Bank of America Securities 2026 Global Healthcare Conference](https://biopharmsignal.com/news/SYK/stryker-to-participate-in-the-bank-of-america-securities-2026-global-healthcare-conference) — Source: Stryker
- 2026-04-30 20:05 EST — [Stryker reports first quarter 2026 operating results](https://biopharmsignal.com/news/SYK/stryker-reports-first-quarter-2026-operating-results) — Source: Stryker
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)